The Middle East and Africa Acute Respiratory Distress Syndrome (ARDS) treatment market is expected to reach USD 302,177.14 thousand by 2030, from USD 164,931.47 thousand in 2022, growing at the CAGR of 8.3% in the forecast period of 2023 to 2030. Market Segmentation Middle East and Africa Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait, and rest of Middle East and Africa) - Industry Trends and Forecast to 2030 Overview of Middle East and Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics Driver • Increasing prevalence and incidence of acute lung injury in the market Restraint • High cost of device and treatment Opportunity • Strategic initiatives joined with new product launches by market players Market Players Some of the major market players operating in the Middle East and Africa Acute Respiratory Distress Syndrome (ARDS) market are listed below: • Gilead Sciences, Inc. • Terumo Medical Corporation • Getinge AB. • LivaNova PLC • Medtronic • ResMed • Fisher & Paykel Healthcare Limited. • Drägerwerk AG & Co. KGaA • NIPRO • Fresenius SE & Co. KGaA • Hamilton Medical • Pfizer Inc. • WEINMANN Emergency Medical Technology GmbH + Co. KG • EUROSETS • Armstrong Medical • nice Neotech Medical Systems Pvt. Ltd. • Besmed Health Business Corp.

1 INTRODUCTION 19 1.1 OBJECTIVES OF THE STUDY 19 1.2 MARKET DEFINITION 19 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 19 1.4 LIMITATIONS 21 1.5 MARKETS COVERED 21 2 MARKET SEGMENTATION 23 2.1 MARKETS COVERED 23 2.2 GEOGRAPHICAL SCOPE 24 2.3 YEARS CONSIDERED FOR THE STUDY 25 2.4 CURRENCY AND PRICING 25 2.5 DBMR TRIPOD DATA VALIDATION MODEL 26 2.6 MULTIVARIATE MODELLING 29 2.7 TYPE LIFELINE CURVE 29 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30 2.9 DBMR MARKET POSITION GRID 31 2.10 MARKET END USER COVERAGE GRID 32 2.11 VENDOR SHARE ANALYSIS 33 2.12 SECONDARY SOURCES 34 2.13 ASSUMPTIONS 34 3 EXECUTIVE SUMMARY 35 4 PREMIUM INSIGHTS 38 4.1 PESTEL ANALYSIS 39 4.2 PORTER’S FIVE FORCES 40 4.3 INSURANCE REIMBURSEMENT 41 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 41 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 41 4.3.3 ABBOTT CODING GUIDE FOR ECMO 42 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 42 4.3.5 CERN HEALTH INSURANCE SCHEME 43 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 43 4.3.7 AMERICAN HOSPITAL ASSOCIATION 44 4.4 PIPELINE ANALYSIS 45 4.5 PRICING ANALYSIS 47 5 MARKET OVERVIEW 48 5.1 DRIVERS 50 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 50 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 50 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 51 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 51 5.2 RESTRAINTS 52 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 52 5.2.2 HIGH COST OF DEVICES AND TREATMENT 52 5.3 OPPORTUNITIES 53 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 53 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 53 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 54 5.4 CHALLENGES 55 5.4.1 STRINGENT RULES & REGULATIONS 55 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 56 6 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 57 6.1 OVERVIEW 58 6.2 MECHANICAL VENTILATION 61 6.2.1 HIGH-FLOW NASAL O2 62 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 62 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 62 6.2.4 PRONE POSITION VENTILATION 62 6.2.5 OTHERS 63 6.3 CORTICOSTEROIDS 63 6.3.1 METHYLPREDNISOLONE 64 6.3.2 DEXAMETHASONE 64 6.3.3 OTHERS 64 6.4 ANTIVIRAL MEDICATION 65 6.4.1 RIBAVIRIN 66 6.4.2 OSELTAMIVIR 66 6.4.3 OTHERS 66 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 66 6.6 TOCILIZUMAB 67 6.7 OTHERS 67 7 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 68 7.1 OVERVIEW 69 7.2 SEPSIS 72 7.3 INHALATION OF HARMFUL SUBSTANCES 72 7.4 SEVERE PNEUMONIA 73 7.5 OTHERS 73 8 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 74 8.1 OVERVIEW 75 8.2 PARENTERAL 78 8.2.1 INTRAVENOUS 78 8.2.2 INTRAMUSCULAR 78 8.3 ORAL 79 8.4 OTHERS 79 9 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 80 9.1 OVERVIEW 81 9.2 HOSPITALS 84 9.3 SPECIALTY CLINICS 84 9.4 HOME HEALTHCARE 85 9.5 OTHERS 85 10 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 86 10.1 OVERVIEW 87 10.2 DIRECT TENDER 90 10.3 HOSPITAL PHARMACY 90 10.4 RETAIL PHARMACY 91 10.5 ONLINE PHARMACY 91 11 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 92 11.1 MIDDLE EAST AND AFRICA 94 11.1.1 SOUTH AFRICA 99 11.1.2 SAUDI ARABIA 104 11.1.3 U.A.E 109 11.1.4 ISRAEL 114 11.1.5 EGYPT 119 11.1.6 KUWAIT 124 11.1.7 REST OF MIDDLE EAST AND AFRICA 129 12 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 130 12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 130 13 SWOT ANALYSIS 131 14 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 132 14.1 GILEAD SCIENCES INC 132 14.1.1 COMPANY SNAPSHOT 132 14.1.2 REVENUE ANALYSIS 133 14.1.3 COMPANY SHARE ANALYSIS 133 14.1.4 PRODUCT PORTFOLIO 134 14.1.5 RECENT DEVELOPMENT 134 14.2 TERUMO CORPORATION 135 14.2.1 COMPANY SNAPSHOT 135 14.2.2 REVENUE ANALYSIS 135 14.2.3 COMPANY SHARE ANALYSIS 136 14.2.4 PRODUCT PORTFOLIO 136 14.2.5 RECENT DEVELOPMENT 136 14.3 GETINGE 137 14.3.1 COMPANY SNAPSHOT 137 14.3.2 REVENUE ANALYSIS 137 14.3.3 COMPANY SHARE ANALYSIS 138 14.3.4 PRODUCT PORTFOLIO 138 14.3.5 RECENT DEVELOPMENT 138 14.4 LIVANOVA PLC 139 14.4.1 COMPANY SNAPSHOT 139 14.4.2 REVENUE ANALYSIS 139 14.4.3 COMPANY SHARE ANALYSIS 140 14.4.4 PRODUCT PORTFOLIO 140 14.4.5 RECENT DEVELOPMENTS 140 14.5 MEDTRONIC 141 14.5.1 COMPANY SNAPSHOT 141 14.5.2 REVENUE ANALYSIS 141 14.5.3 COMPANY SHARE ANALYSIS 142 14.5.4 PRODUCT PORTFOLIO 142 14.5.5 RECENT DEVELOPMENTS 142 14.6 ARMSTRONG MEDICAL 143 14.6.1 COMPANY SNAPSHOT 143 14.6.2 PRODUCT PORTFOLIO 143 14.6.3 RECENT DEVELOPMENT 143 14.7 BESMED HEALTH BUSINESS CORP 144 14.7.1 COMPANY SNAPSHOT 144 14.7.2 PRODUCT PORTFOLIO 144 14.7.3 RECENT DEVELOPMENTS 145 14.8 DRÄGERWERK AG & CO. KGAA 146 14.8.1 COMPANY SNAPSHOT 146 14.8.2 REVENUE ANALYSIS 146 14.8.3 PRODUCT PORTFOLIO 147 14.8.4 RECENT DEVELOPMENTS 147 14.9 EUROSETS 148 14.9.1 COMPANY SNAPSHOT 148 14.9.2 PRODUCT PORTFOLIO 148 14.9.3 RECENT DEVELOPMENT 148 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 149 14.10.1 COMPANY SNAPSHOT 149 14.10.2 REVENUE ANALYSIS 149 14.10.3 PRODUCT PORTFOLIO 150 14.10.4 RECENT DEVELOPMENTS 150 14.11 FRESENIUS SE & CO. KGAA 151 14.11.1 COMPANY SNAPSHOT 151 14.11.2 REVENUE ANALYSIS 151 14.11.3 PRODUCT PORTFOLIO 152 14.11.4 RECENT DEVELOPMENT 152 14.12 HAMILTON MEDICAL 153 14.12.1 COMPANY SNAPSHOT 153 14.12.2 PRODUCT PORTFOLIO 153 14.12.3 RECENT DEVELOPMENT 153 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 154 14.13.1 COMPANY SNAPSHOT 154 14.13.2 PRODUCT PORTFOLIO 154 14.13.3 RECENT DEVELOPMENT 154 14.14 NIPRO 155 14.14.1 COMPANY SNAPSHOT 155 14.14.2 REVENUE ANALYSIS 155 14.14.3 PRODUCT PORTFOLIO 156 14.14.4 RECENT DEVELOPMENT 156 14.15 PFIZER INC 157 14.15.1 COMPANY SNAPSHOT 157 14.15.2 REVENUE ANALYSIS 157 14.15.3 PRODUCT PORTFOLIO 158 14.15.4 RECENT DEVELOPMENT 158 14.16 RESMED 159 14.16.1 COMPANY SNAPSHOT 159 14.16.2 REVENUE ANALYSIS 159 14.16.3 PRODUCT PORTFOLIO 160 14.16.4 RECENT DEVELOPMENT 160 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 161 14.17.1 COMPANY SNAPSHOT 161 14.17.2 PRODUCT PORTFOLIO 161 14.17.3 RECENT DEVELOPMENT 161 15 QUESTIONNAIRE 162 16 RELATED REPORTS 165